These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 16945954)

  • 21. RNAi prodrugs decrease elevated mRNA levels of Polo-like kinase 1 in ex vivo cultured primary cells from pediatric acute myeloid leukemia patients.
    Kolosenko I; Goroshchuk O; Vidarsdottir L; Björklund AC; Dowdy SF; Palm-Apergi C
    FASEB J; 2021 May; 35(5):e21476. PubMed ID: 33788972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals.
    Guan R; Tapang P; Leverson JD; Albert D; Giranda VL; Luo Y
    Cancer Res; 2005 Apr; 65(7):2698-704. PubMed ID: 15805268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
    Lin YC; Sun SH; Wang FF
    Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adenovirus-mediated Aurora A shRNA driven by stathmin promoter suppressed tumor growth and enhanced paclitaxel chemotherapy sensitivity in human breast carcinoma cells.
    Long M; Yin G; Liu L; Lin F; Wang X; Ren J; Wei J; Dong K; Zhang H
    Cancer Gene Ther; 2012 Apr; 19(4):271-81. PubMed ID: 22281755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced gemcitabine-mediated cell killing of human lung adenocarcinoma by vector-based RNA interference against PLK1.
    Zhao XY; Nie CL; Liang SF; Yuan Z; Deng HX; Wei YQ
    Biomed Pharmacother; 2012 Dec; 66(8):597-602. PubMed ID: 23153503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma.
    Duan Z; Ji D; Weinstein EJ; Liu X; Susa M; Choy E; Yang C; Mankin H; Hornicek FJ
    Cancer Lett; 2010 Jul; 293(2):220-9. PubMed ID: 20144850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.
    Bhola NE; Jansen VM; Bafna S; Giltnane JM; Balko JM; Estrada MV; Meszoely I; Mayer I; Abramson V; Ye F; Sanders M; Dugger TC; Allen EV; Arteaga CL
    Cancer Res; 2015 Jan; 75(2):405-14. PubMed ID: 25480943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of antitumor immunity using dendritic cells electroporated with Polo-like kinase 1 (Plk1) mRNA in murine tumor models.
    Park JS; Sohn HJ; Park GS; Chung YJ; Kim TG
    Cancer Sci; 2011 Aug; 102(8):1448-54. PubMed ID: 21545375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting polo-like kinase 1 for cancer therapy.
    Strebhardt K; Ullrich A
    Nat Rev Cancer; 2006 Apr; 6(4):321-30. PubMed ID: 16557283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma.
    Evans RP; Dueck G; Sidhu R; Ghosh S; Toman I; Loree J; Bahlis N; Klimowicz AC; Fung J; Jung M; Lai R; Pilarski LM; Belch AR; Reiman T
    Leuk Res; 2011 Dec; 35(12):1637-43. PubMed ID: 21816470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel oncolytic adenovirus selectively targets tumor-associated polo-like kinase 1 and tumor cell viability.
    Zhou J; Gao Q; Chen G; Huang X; Lu Y; Li K; Xie D; Zhuang L; Deng J; Ma D
    Clin Cancer Res; 2005 Dec; 11(23):8431-40. PubMed ID: 16322306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting Polo-like Kinase 1 by a Novel Pyrrole-Imidazole Polyamide-Hoechst Conjugate Suppresses Tumor Growth
    Liu K; Fang L; Sun H; Pan Z; Zhang J; Chen J; Shao X; Wang W; Tan Y; Ding Z; Ao L; Wu C; Liu X; Li H; Wang R; Su W; Li H
    Mol Cancer Ther; 2018 May; 17(5):988-1002. PubMed ID: 29483218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53-dependent repression of polo-like kinase-1 (PLK1).
    McKenzie L; King S; Marcar L; Nicol S; Dias SS; Schumm K; Robertson P; Bourdon JC; Perkins N; Fuller-Pace F; Meek DW
    Cell Cycle; 2010 Oct; 9(20):4200-12. PubMed ID: 20962589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.
    Gilmartin AG; Bleam MR; Richter MC; Erskine SG; Kruger RG; Madden L; Hassler DF; Smith GK; Gontarek RR; Courtney MP; Sutton D; Diamond MA; Jackson JR; Laquerre SG
    Cancer Res; 2009 Sep; 69(17):6969-77. PubMed ID: 19690138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.
    Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
    Chem Biol; 2008 May; 15(5):459-66. PubMed ID: 18482698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of Plk1 induces mitotic infidelity and embryonic growth defects in developing zebrafish embryos.
    Jeong K; Jeong JY; Lee HO; Choi E; Lee H
    Dev Biol; 2010 Sep; 345(1):34-48. PubMed ID: 20553902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1.
    Feng B; Wang R; Chen LB
    Cancer Lett; 2012 Apr; 317(2):184-91. PubMed ID: 22120675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.
    Steegmaier M; Hoffmann M; Baum A; Lénárt P; Petronczki M; Krssák M; Gürtler U; Garin-Chesa P; Lieb S; Quant J; Grauert M; Adolf GR; Kraut N; Peters JM; Rettig WJ
    Curr Biol; 2007 Feb; 17(4):316-22. PubMed ID: 17291758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PLK1 signaling in breast cancer cells cooperates with estrogen receptor-dependent gene transcription.
    Wierer M; Verde G; Pisano P; Molina H; Font-Mateu J; Di Croce L; Beato M
    Cell Rep; 2013 Jun; 3(6):2021-32. PubMed ID: 23770244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Normal cells, but not cancer cells, survive severe Plk1 depletion.
    Liu X; Lei M; Erikson RL
    Mol Cell Biol; 2006 Mar; 26(6):2093-108. PubMed ID: 16507989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.